%0 Journal Article
%T CSK may be a potential prognostic biomarker reflecting the immune status of gastric cancer.
%A Yan X
%A Huan J
%J Eur Rev Med Pharmacol Sci
%V 28
%N 1
%D 2024 Jan
%M 38235873
%F 3.784
%R 10.26355/eurrev_202401_34907
%X <B>OBJECTIVE: </B>C-terminal Src kinase (CSK), a sarcoma (Src) homologous family kinase, is one of the most important negative regulators. It acts as a tumor suppressor by inhibiting the activity of Src family tyrosine kinases. Paradoxically, CSK is highly expressed in a variety of common tumors. Therefore, we report the expression profile of CSK in pan-cancer patients, focusing on the prognostic value, immune infiltration pattern, and biological function of CSK in gastric cancer.<BR><B>METHODS: </B>We used the TCGA database to analyze CSK expression, clinical relevance, prognostic significance, assessment of the tumor immune microenvironment, and GO and Kegg enrichment analysis based on co-expressed genes using a bioinformatics approach.<BR><B>RESULTS: </B>CSK is a protective factor in gastric cancer, and its expression correlates with the level of immune cell infiltration and immune checkpoint molecules.<BR><B>CONCLUSIONS: </B>Our findings suggest that CSK is an independent prognostic factor in gastric cancer and may predict molecular targeting and immunotherapy and provide ideas for its therapeutic strategy.